Navigation Links
Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
Date:4/7/2008

PLYMOUTH MEETING, Pa., April 7, 2008 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 contained an unqualified audit opinion from its independent registered public accounting firm, KPMG LLP, which included a "going concern" explanatory paragraph. The Company discusses this matter, including its plans to address future financing needs, in Note 1 to the financial statements included in its Form 10-K.

This disclosure is required under NASDAQ rules and does not represent any change or amendment to the Company's 2007 financial statements or to its Annual Report on Form 10-K which was filed on March 31, 2008 with the Securities and Exchange Commission.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at http://www.genaera.com.

This announcement contains forward-looking statements within the me
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Brooke Franchise Corporation Announces Selected July Results
5. MedThink Communications Retained by NanoBio Corporation
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Nov. 27 GSI Group Inc. ... precision technology products and semiconductor s...the Company,s shareholders has been scheduled for ...the meeting will be announced in due course. As p...ition notice from Stephen Bershad, a holder of gre...
(Date:11/27/2009)... Considered a highly ris...rs ago, solid organ transplantation is now a life-...inary men and women who gathered at the Winspear O...ther from medical centers around the world to cele...splant Institute (BRTI), one of the pioneers of so...
(Date:11/27/2009)...INE, France, Nov. 27 Team Garmin-S... team dedicated to ethical sporting and developing...ed today that it will become Team Garmin-Transitio...ew sponsor of the team. Transitions Optical is the... offering the most advanced photochromic technolog...
(Date:11/27/2009)...-emission vehicles may reduce future disease burde...HealthDay News) -- Encouraging city dwellers to wa...uch greater public health benefits than increased ...ve found. , The study compared the projected he...nsport scenarios for London, England, and Delhi, I...
(Date:11/27/2009)...yant Health™ announced today that Spectrum H...aumaCad Enterprise orthopedic templating solution ... (PRWEB) November 27, 2009 -- ... Health (Grand Rapids, Michigan) has licensed its ...n and its TraumaCad Extend workflow solution, to a...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...Percent for the Year , , PITTSBURGH, Feb. 26 MSA... the year ended December 31, 2008 were $1,134.3 mi...rease of $144.0 million, or 15 percent. Net incom...lion, or $1.89 per basic share, for 2007. Net inc...
... Feb. 26 Accuray Incorporated,(Nasdaq: ARAY ), ...y announced,highlights from the clinical and techn...Users, Meeting, which was held February 4-7, 2009,...otic,Radiosurgery System for the non-invasive trea...
... Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to...ant purchase order for the MammoView(TM) line of s...tal in Connecticut. The Waterbury Hospital, the c...he Joint Commission on the Accreditation of Health...
...ss, more peace after sessions, study finds , ...n improve the emotional health of breast cancer pa...gh levels of stress and distress that many women w...ad researcher Suzanne Danhauer, of the Wake Forest...
.... 26 Garry W. Rogerson, Chairman and CEO of Varia...s Capital Global Healthcare Conference in Miami on...ime. , , A live webcast of the presentation will ...ived replay will be available to the public from V...
...iced Nonadhesive Ventral Hernia Meshes Climbs in L...up , , WALTHAM, Mass., Feb. 26 According to Mill...n Markets for Hernia Repair Devices 2009 repo..., lower risk of infection, and lower recurrence ra...
Other Medicine News:Health News:MSA Announces Record Fourth Quarter and Full Year Sales 2Health News:MSA Announces Record Fourth Quarter and Full Year Sales 3Health News:MSA Announces Record Fourth Quarter and Full Year Sales 4Health News:MSA Announces Record Fourth Quarter and Full Year Sales 5Health News:MSA Announces Record Fourth Quarter and Full Year Sales 6Health News:MSA Announces Record Fourth Quarter and Full Year Sales 7Health News:MSA Announces Record Fourth Quarter and Full Year Sales 8Health News:Clinical Evidence Grows in Support of CyberKnife Treatment for Intracranial and Extracranial Tumors 2Health News:Clinical Evidence Grows in Support of CyberKnife Treatment for Intracranial and Extracranial Tumors 3Health News:Clinical Evidence Grows in Support of CyberKnife Treatment for Intracranial and Extracranial Tumors 4Health News:Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM) 2Health News:Yoga May Bring Calm to Breast Cancer Treatment 2Health News:Latin American Market for Hernia Repair Devices Achieving Double-Digit Growth 2
(Date:11/25/2009)... -- BioTrends Research Group, Inc. released Wave 1...the first in a multi-phase syndicated market resea...Biotech,s Stelara, from product launch through the...he report provides quantitative information from 7...n from a subset of 20. The reports assess trial a...
(Date:11/25/2009)... For many of the millions...million living with untreated hearing loss , the ...st Cindy Beyer. ,, Dr. Beyer, senior vice presi...rgest hearing care and hearing aids companies, s...ustration, and social isolation, "which can easily...
(Date:11/25/2009)...PRNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a s... APFC ) announced today that it received the Envi...at the Annual Statewide Environmental Summit, spon...gy Association (CMTA), the Industrial Environmenta...cil of California (CICC) held in San Diego. This ...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Cruise Ship Virus Vaccine Stems From Tobacco 54758 1Cruise Ship Virus Vaccine Stems From Tobacco 54758 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 1PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 3Bankrupt Medicare to be Burdened With 24Billions More for Translation Costs Says ProEnglish 54750 1
...presented at the 90th annual Endocrine Society mee...ected by moderate to severe vaginal ...Mich, June 16 QuatRx Pharmaceuticals today,announ...al Phase 3 clinical,trial of Ophena(TM) (ospemifen...toms of vulvovaginal atrophy, a common condition a...
...lished in the Journal of the American Society of H...giotensin II reversed vascular ... A new study published in the,current Journal of t...hat,the hypertension treatment olmesartan medoxomi...arteries that occurs in patients with hypertension...
Other Medicine Technology:Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 2New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 3New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 5New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 6New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 7New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 8New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 9
...choices for finishing. The first choice was to pro...eant longer delay to deliver the order. The altern...eant a substantial investment when additional offi...pace and employee training. TOPscan Remote Tracing...
...rate, and reliable tests of a wide variety of visu...ditions for viewing far point test charts at 5 met...est charts at 30cm (12"). The SS-3, which is very ...an be interchanged as required. The tests show, fo...
Topcon OM-B1 Opthalmometer
... standard in powerful imaging software, and a Comp...ble an easy to use color fundus screening package....gital imaging software with Topcons Non-Mydriatic ...ghly accurate color-digital retinopathy screenings...
Medicine Products: